Publication:
Factors Affecting Relapse and Remission in Behcet's Uveitis Treated with Interferon Alpha2a

dc.contributor.authorÇELİKER ATABERK, HANDE
dc.contributor.authorDİRESKENELİ, RAFİ HANER
dc.contributor.authorsCeliker, Hande; Kazokoglu, Haluk; Direskeneli, Haner
dc.date.accessioned2022-03-12T22:24:30Z
dc.date.accessioned2026-01-11T15:20:13Z
dc.date.available2022-03-12T22:24:30Z
dc.date.issued2019
dc.description.abstractPurpose: To investigate factors affecting relapse and remission in patients with Behcet uveitis (BU) in the context of using the interferon alpha2a (IFN alpha 2a) therapy. Methods: Clinical records were reviewed of 32 patients (totaling 54 eyes) presenting with severe BU who had been treated with IFN alpha 2a therapy. Factors influencing relapsing-remitting course of BU during IFN alpha 2a therapy and after the cessation of the agent were evaluated. Possible affecting factors of recurrence were age, gender, duration of the Behcet disease, time elapsed before starting the drug, number of relapses before the starting of IFN alpha 2a, laterality, and presence of panuveitis. Results: Thirty patients (93.7%) responded to IFN alpha 2a therapy. Annual attack rate before and after IFN alpha 2a treatment was determined to be 4.03 +/- 3.19 (attack per year) and 0.58 +/- 1.07, respectively (P<0.001). In univariable statistical evaluation, women tended to have a lower relapse risk than men. Multivariable analyses showed that age was the major factor determining relapse rate, while the effect of gender was not statistically significant (P=0.196). The other probable influencing factors were not found to be statistically significant (P>0.05). Increase in visual acuity observed during last examination compared to initial examination was determined to be statistically significant (P=0.018). Conclusions: Even if the female gender was evaluated as a good prognostic factor in univariable analyses, it was not assessed as an effective prognostic factor in multivariable analyses. Being aged may be regarded a good prognostic factor on the relapsing-remitting course of patients with BU who were treated with IFN alpha 2a therapy.
dc.identifier.doi10.1089/jop.2018.0083
dc.identifier.eissn1557-7732
dc.identifier.issn1080-7683
dc.identifier.pubmed30359208
dc.identifier.urihttps://hdl.handle.net/11424/234777
dc.identifier.wosWOS:000448383500001
dc.language.isoeng
dc.publisherMARY ANN LIEBERT, INC
dc.relation.ispartofJOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBehcet disease
dc.subjectBehcet uveitis
dc.subjectIFN alpha 2a
dc.subjectinterferons
dc.subjectrelapse
dc.subjectuveitis
dc.subjectLONG-TERM EFFICACY
dc.subjectPROGNOSTIC-FACTORS
dc.subjectVISUAL PROGNOSIS
dc.subjectDISEASE
dc.subjectTHERAPY
dc.subjectSAFETY
dc.subjectINFLIXIMAB
dc.subjectINVOLVEMENT
dc.subjectMANAGEMENT
dc.titleFactors Affecting Relapse and Remission in Behcet's Uveitis Treated with Interferon Alpha2a
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage65
oaire.citation.issue1
oaire.citation.startPage58
oaire.citation.titleJOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
oaire.citation.volume35

Files